期刊文献+

美罗列汀的合成 被引量:1

Synthesis of melogliptin
原文传递
导出
摘要 目的:合成二肽激肽酶IV抑制剂美罗列汀,并对工艺进行改进。方法:以(±)-2-氮杂双环[2,2,1]庚-5-烯-3-酮(2)为起始原料,通过氨基保护、还原、缩合等10步反应合成美罗列汀。结果:目标产物的结构经1H-NMR,13C-NMR和ESI-MS确证,总收率为13%。结论:该合成路线操作简单,反应条件温和,收率较高。 Objective: To synthesize melogliptin, a dipeptidyl peptidase IV inhibitor, and optimize the preparation process. Methods: The target compound was synthesized from ( ± )-2-azabiayclo [ 2,2,1 ] hept-5-en-3- one (2) by ten steps including protection, reduction and condensation. Results: The structure of melogliptin was confirmed by ^9H-NMR, 13^C-NMR and ESI-MS. The overall yield was 13%. Conclusion: This synthetic process needs mild reaction condition, which is easy to operate with high yield.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第23期2786-2789,共4页 Chinese Journal of New Drugs
关键词 美罗列汀 二肽激肽酶IV抑制剂 合成 melogliptin dipeptidyl peptidase IV inhibitors synthesis
  • 相关文献

参考文献7

  • 1Glenmark Pharmaceutical Ltd. Glenmark's novel molecule for Diahetes,Melogliptin to enter phase III trials [EB/OLJ. [2014 -4- 10]. http://www.glenmarkpharma.com/GLN _ NWS/pdflGlenmarks_noveL molecule _for _ Diabetes _ Melogliptin _phase _ IHtrail. pdf.
  • 2THOMAS A,LINGAM VS,KADAM AB,et al, Novel processes for the preparation of DPP IV inhibitors: WO, 2008001195 [P] . 2008 -01 -03.
  • 3THOMAS A, GOP ALAN B, LINGAM P, et al. Novel dipeptidyl peptidase IV inhibitors, pharmaceutical composition containing them and process for their preparation: W 0 , 2006040625 [P] . 2006 - 04 - 20.
  • 4GOPALAN B, RAYI D, RASHEED M ,et al, Novel dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them: WO, 2007113634 [P]. 2007 - 10 - 11.
  • 5BALASVBRAMANIAN G, SAKAMVRI S, SINGH G, et al. Dipeptidyl peptidase IV inhibitors: WO 2010079413 [P]. 2010 - 07 - 15.
  • 6RAJENDRA P, SINGH, TERVO V. 4-fluoropyrrolidine-2-carbonyl fluorides: useful synthons and their facile preparation with 4-tertbutyl-2 ,6-dimethylphenylsulfur trifluoride [J]. J Org Chem ,2011, 76(9) :3113 -3121.
  • 7ENIKO F, FERENC F. Enzymatic method for the synthesis of blockbuster drug intermediates-synthesis of five-membered cyclic -v-amino acid and -y-lactam enantiomers [J]. Eur J Org Chem, 2008, 31 (2008) :5263 - 5268.

同被引文献7

  • 1石药集团.石药集团与台湾健亚正式签署合作协议开发抗糖尿病新药DBPRl08[EB/OL].(2013-01-05).http://www.e-cspc.corn/news-company-detail.aspx?id=1019.
  • 2国家卫生研究院.本院生技与药物研究所新颖抗糖尿病候选药物DBPRl08经合作厂商接力开发,获大陆国家食品药品监督管理总局(CFDA)核发同意进行第一期临床试验[EB/OL]. (2015 -04 - 16). http://www, nhri. org. tw/NHRI_WEB/ nhriw001Action do.'? status=Show_Dtl&nid =2015041675081773 0000&uid = 20081203749159640000.
  • 3YEIq TK,TSAI TY ,FISU TSU ,et al. (2S,4S) -1-[2-( 1,1 -Dimeth- yl-3-oxo-3-pyrrolidin-l-yl-propylamino ) acetyl ]-4-fluoro-pyrroli- dine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV [ J ]. Bioorg Med Chem Lett ,2010,20 (12) :3596 - 3600.
  • 4JIAANG WT, CHAO YS, YUEH TT, et al. Pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors useful in the treatment of type II diabetes and their preparation : WO, 2009111239 [ P 1. 2009 - 09 - 11.
  • 5HAESELER PR. Diacetoneamine hydrogen oxalate [ J ]. Org Synth, 1926,6(1) :28 -30.
  • 6SANDBORN LT, BOUSQUET EW. Trimethylacetic acid [J]. Org Synth,1928,8(lO) :104 - 110.
  • 7李祎亮,王菊仙,吴香玫,邹美香,李卓荣,王玉成.二肽基肽酶Ⅳ抑制剂的研究进展[J].中国新药杂志,2008,17(20):1739-1745. 被引量:11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部